Financial Review: Talphera (NASDAQ:TLPH) versus Scienture (NASDAQ:SCNX)

Talphera (NASDAQ:TLPH) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares Talphera and Scienture”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$1,000.00	62,287.20	-$14.29 million	($0.27)	-4.44
Scienture	$430,000.00	35.62	-$41.51 million	($2.10)	-0.18

Talphera has higher earnings, but lower revenue than Scienture. Talphera is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Talphera and Scienture, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	1	2	0	2.25
Scienture	1	0	1	0	2.00

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 150.00%. Scienture has a consensus price target of $1.50, indicating a potential upside of 302.14%. Given Scienture’s higher possible upside, analysts clearly believe Scienture is more favorable than Talphera.

Profitability

This table compares Talphera and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Scienture	N/A	-53.51%	-42.47%

Insider and Institutional Ownership

37.7% of Talphera shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 21.4% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Talphera has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.25, suggesting that its share price is 225% more volatile than the S&P 500.

Summary

Scienture beats Talphera on 7 of the 13 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.